Straits Times Index
3,201.89 +10.73 (+0.34%) S&P 500
4,088.85 +80.84 (+2.02%) Dow
32,654.59 +431.17 (+1.34%) Nasdaq
11,984.52 +321.73 (+2.76%) BTC-USD
30,516.31 +425.09 (+1.41%) CMC Crypto 200
677.94 +435.26 (+179.36%)
Novo Nordisk A/S (NONOF)
| Previous close | 103.55 |
| Open | 108.03 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 104.13 - 109.00 |
| 52-week range | 76.75 - 123.70 |
| Volume | |
| Avg. volume | 13,910 |
| Market cap | 249.445B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 36.26 |
| EPS (TTM) | 3.01 |
| Earnings date | N/A |
| Forward dividend & yield | 1.57 (1.52%) |
| Ex-dividend date | 25 Mar 2022 |
| 1y target est | N/A |
- Zacks
Lilly's (LLY) Diabetes Treatment Tirzepatide Gets FDA Nod
Lilly's (LLY) Mounjaro (tirzepatide) is a novel diabetes treatment, which has shown impressive blood sugar reductions and weight loss in a broad range of type II diabetes patients in the SURPASS studies.
- Motley Fool
3 Unstoppable Stocks to Buy in May
Prosper Junior Bakiny (Novo Nordisk): For the past several decades, Novo Nordisk has been a leader in the market for diabetes drugs. As of February 2022, the company held a 30.5% share of the diabetes care market, an increase from the 29.3% slice of the pie it had in February 2021. Novo Nordisk's dominance in this therapeutic area is one reason it has outperformed the broader market in each of the past one, five, 10, and 20 years.
- Zacks
Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus
Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.
